Not necessarily as a named segment
It provides early evidence that future studies are worth pursuing. ASCO expert Martin Tristek, Chief of Supportive Oncology and Palliative Care at Fox Chase Cancer Center, went further, noting that GLP-1s have never been just glucose-lowering drugs and that the consistency across tumor types warrants a prospective randomized trial. ASCO Chief Medical Officer Julie Gralow emphasized that the findings showed a reduction of metastatic recurrence in those already diagnosed with cancer but cautioned that only a randomized trial can prove causation
Through a combination of drumming, education, humor and calling in, Rahul has been just the facilitator weve needed and will continue to call on as we forge ahead in this work
only, and this is going to be interesting to see because not only biosimilars are going to be introduced in 2023, but theres going to be multiple biosimilars of Humira introduced this year
In addition, an active (glipizide)-controlled study of 52-weeks duration was conducted in 1172 patients with type 2 diabetes who had inadequate glycemic control on metformin
It helps reduce signs of aging and boost skin renewal
